FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1843927557> ?p ?o ?g. }

• W1843927557 endingPage "50" @default.
• W1843927557 startingPage "5443" @default.
• W1843927557 abstract "Some murine melanomas and hepatocellular carcinomas (HCCs) have been shown to be auxotrophic for arginine. Arginine deiminase (ADI; EC 3.5.3.6.), an arginine-degrading enzyme isolated from Mycoplasma, can inhibit growth of these tumors. We found that ADI was specific for arginine and did not degrade other amino acids. Although arginine is not an essential amino acid for most cells, all human melanomas and HCCs tested were found to be inhibited by ADI in vitro. Arginine is synthesized from citrulline in two steps by argininosuccinate synthetase and argininosuccinate lyase. Melanomas and HCCs did not express argininosuccinate synthetase mRNA but did express argininosuccinate lyase mRNA, suggesting that the arginine auxotrophy of these cells was a result of an inability to produce argininosuccinate synthetase. Human melanomas and HCCs were transfected with an expression plasmid containing argininosuccinate synthetase cDNA. The transfected cells were much more resistant to ADI than the parental cells in vitro and in vivo. Initial attempts to use ADI in vivo indicated that this enzyme had little efficacy, consistent with its short circulation half-life. Formulation of ADI with polyethylene glycol to produce ADI-SS PEG(20,000 mw) resulted in an enzyme with a much longer circulation half-life that, and although equally effective in vitro, was more efficacious in the treatment of mice implanted with human melanomas and HCCs. These data indicate that sensitivity of melanoma and HCC is due to the absence of argininosuccinate synthetase in these cells and that an effective formulation of ADI, which causes a sustained decrease in arginine, may be a useful treatment for arginine auxotrophic tumors including melanoma and HCC." @default.
• W1843927557 created "2016-06-24" @default.
• W1843927557 creator A5001085802 @default.
• W1843927557 creator A5007808102 @default.
• W1843927557 creator A5054417921 @default.
• W1843927557 creator A5080515356 @default.
• W1843927557 date "2002-10-01" @default.
• W1843927557 modified "2023-09-28" @default.
• W1843927557 title "Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo." @default.
• W1843927557 cites W1583557220 @default.
• W1843927557 cites W1612369991 @default.
• W1843927557 cites W1789352132 @default.
• W1843927557 cites W187549244 @default.
• W1843927557 cites W1954112072 @default.
• W1843927557 cites W1969088808 @default.
• W1843927557 cites W1982933638 @default.
• W1843927557 cites W1988602640 @default.
• W1843927557 cites W1992930117 @default.
• W1843927557 cites W2018333136 @default.
• W1843927557 cites W2019470388 @default.
• W1843927557 cites W2088404799 @default.
• W1843927557 cites W2125712394 @default.
• W1843927557 cites W2320990756 @default.
• W1843927557 cites W2411877572 @default.
• W1843927557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12359751" @default.
• W1843927557 hasPublicationYear "2002" @default.
• W1843927557 type Work @default.
• W1843927557 sameAs 1843927557 @default.
• W1843927557 citedByCount "99" @default.
• W1843927557 countsByYear W18439275572012 @default.
• W1843927557 countsByYear W18439275572013 @default.
• W1843927557 countsByYear W18439275572014 @default.
• W1843927557 countsByYear W18439275572015 @default.
• W1843927557 countsByYear W18439275572016 @default.
• W1843927557 countsByYear W18439275572017 @default.
• W1843927557 countsByYear W18439275572018 @default.
• W1843927557 countsByYear W18439275572019 @default.
• W1843927557 countsByYear W18439275572020 @default.
• W1843927557 countsByYear W18439275572021 @default.
• W1843927557 countsByYear W18439275572022 @default.
• W1843927557 countsByYear W18439275572023 @default.
• W1843927557 crossrefType "journal-article" @default.
• W1843927557 hasAuthorship W1843927557A5001085802 @default.
• W1843927557 hasAuthorship W1843927557A5007808102 @default.
• W1843927557 hasAuthorship W1843927557A5054417921 @default.
• W1843927557 hasAuthorship W1843927557A5080515356 @default.
• W1843927557 hasConcept C104317684 @default.
• W1843927557 hasConcept C150903083 @default.
• W1843927557 hasConcept C153911025 @default.
• W1843927557 hasConcept C164007495 @default.
• W1843927557 hasConcept C181199279 @default.
• W1843927557 hasConcept C185592680 @default.
• W1843927557 hasConcept C188610204 @default.
• W1843927557 hasConcept C202751555 @default.
• W1843927557 hasConcept C207001950 @default.
• W1843927557 hasConcept C2776761436 @default.
• W1843927557 hasConcept C2777186326 @default.
• W1843927557 hasConcept C2777468819 @default.
• W1843927557 hasConcept C2778019345 @default.
• W1843927557 hasConcept C2779129087 @default.
• W1843927557 hasConcept C2779314089 @default.
• W1843927557 hasConcept C502942594 @default.
• W1843927557 hasConcept C515207424 @default.
• W1843927557 hasConcept C54009773 @default.
• W1843927557 hasConcept C55493867 @default.
• W1843927557 hasConcept C86803240 @default.
• W1843927557 hasConceptScore W1843927557C104317684 @default.
• W1843927557 hasConceptScore W1843927557C150903083 @default.
• W1843927557 hasConceptScore W1843927557C153911025 @default.
• W1843927557 hasConceptScore W1843927557C164007495 @default.
• W1843927557 hasConceptScore W1843927557C181199279 @default.
• W1843927557 hasConceptScore W1843927557C185592680 @default.
• W1843927557 hasConceptScore W1843927557C188610204 @default.
• W1843927557 hasConceptScore W1843927557C202751555 @default.
• W1843927557 hasConceptScore W1843927557C207001950 @default.
• W1843927557 hasConceptScore W1843927557C2776761436 @default.
• W1843927557 hasConceptScore W1843927557C2777186326 @default.
• W1843927557 hasConceptScore W1843927557C2777468819 @default.
• W1843927557 hasConceptScore W1843927557C2778019345 @default.
• W1843927557 hasConceptScore W1843927557C2779129087 @default.
• W1843927557 hasConceptScore W1843927557C2779314089 @default.
• W1843927557 hasConceptScore W1843927557C502942594 @default.
• W1843927557 hasConceptScore W1843927557C515207424 @default.
• W1843927557 hasConceptScore W1843927557C54009773 @default.
• W1843927557 hasConceptScore W1843927557C55493867 @default.
• W1843927557 hasConceptScore W1843927557C86803240 @default.
• W1843927557 hasIssue "19" @default.
• W1843927557 hasLocation W18439275571 @default.
• W1843927557 hasOpenAccess W1843927557 @default.
• W1843927557 hasPrimaryLocation W18439275571 @default.
• W1843927557 hasRelatedWork W1554531402 @default.
• W1843927557 hasRelatedWork W1631387439 @default.
• W1843927557 hasRelatedWork W1833932539 @default.
• W1843927557 hasRelatedWork W1843927557 @default.
• W1843927557 hasRelatedWork W2014450630 @default.
• W1843927557 hasRelatedWork W2066858504 @default.
• W1843927557 hasRelatedWork W2119097025 @default.
• W1843927557 hasRelatedWork W2511312568 @default.

• next